BCG024 / Biocytogen - LARVOL DELTA

BCG024: A novel DLL3×CD3×4-1BB trispecific T cell engager enhances T cell persistence and functionality in preclinical models (AACR 2026) - "Our DLL3×CD3×4-1BB TriAb demonstrates tumor-dependent co-stimulation, enhanced T cell persistence and functionality, further exhibiting superior anti-tumor efficacy in preclinical SCLC model and good safety profiles at high dose. These findings highlight the DLL3 TriAb as a next-generation immunotherapy, offering enhanced T cell functionality and clinical translatability."

Preclinical • Trispecific • Hematological Malignancies • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • DLL3